Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Other Operating Expenses (2021 - 2024)

Historic Other Operating Expenses for Amylyx Pharmaceuticals (AMLX) over the last 3 years, with Q3 2024 value amounting to $37.0 million.

  • Amylyx Pharmaceuticals' Other Operating Expenses rose 60931.39% to $37.0 million in Q3 2024 from the same period last year, while for Jun 2025 it was $37.0 million, marking a year-over-year decrease of 7325.76%. This contributed to the annual value of $160.8 million for FY2024, which is 53219.21% up from last year.
  • Per Amylyx Pharmaceuticals' latest filing, its Other Operating Expenses stood at $37.0 million for Q3 2024, which was up 60931.39% from $7.4 million recorded in Q2 2024.
  • Amylyx Pharmaceuticals' Other Operating Expenses' 5-year high stood at $116.4 million during Q1 2024, with a 5-year trough of $172000.0 in Q3 2022.
  • Over the past 3 years, Amylyx Pharmaceuticals' median Other Operating Expenses value was $5.6 million (recorded in 2023), while the average stood at $21.0 million.
  • In the last 5 years, Amylyx Pharmaceuticals' Other Operating Expenses skyrocketed by 293372.09% in 2023 and then skyrocketed by 3293.91% in 2024.
  • Over the past 3 years, Amylyx Pharmaceuticals' Other Operating Expenses (Quarter) stood at $2.8 million in 2022, then surged by 231.8% to $9.4 million in 2023, then skyrocketed by 295.43% to $37.0 million in 2024.
  • Its last three reported values are $37.0 million in Q3 2024, $7.4 million for Q2 2024, and $116.4 million during Q1 2024.